Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 313 to 319 of 319 entries
Sorted by: Best Match Show Resources per page
'It's literally giving them a solution in their hands': the views of young Australians towards patient-delivered partner therapy for treating chlamydia.

Sexually transmitted infections

Layton E, Goller JL, Coombe J, Temple-Smith M, Tomnay J, Vaisey A, Hocking JS.
PMID: 33441448
Sex Transm Infect. 2021 Jun;97(4):256-260. doi: 10.1136/sextrans-2020-054820. Epub 2021 Jan 13.

OBJECTIVES: Patient-delivered partner therapy (PDPT) is a method for providing antibiotic treatment for the sexual partners of an index patient with an STI by means of a prescription or medication that the index patient gives to their sexual partner(s)....

Cite
Layton E, Goller JL, Coombe J, et al. 'It's literally giving them a solution in their hands': the views of young Australians towards patient-delivered partner therapy for treating chlamydia. Sex Transm Infect. 2021;97(4):256-260doi: 10.1136/sextrans-2020-054820.
Layton, E., Goller, J. L., Coombe, J., Temple-Smith, M., Tomnay, J., Vaisey, A., & Hocking, J. S. (2021). 'It's literally giving them a solution in their hands': the views of young Australians towards patient-delivered partner therapy for treating chlamydia. Sexually transmitted infections, 97(4), 256-260. https://doi.org/10.1136/sextrans-2020-054820
Layton, Elly, et al. "'It's literally giving them a solution in their hands': the views of young Australians towards patient-delivered partner therapy for treating chlamydia." Sexually transmitted infections vol. 97,4 (2021): 256-260. doi: https://doi.org/10.1136/sextrans-2020-054820
Layton E, Goller JL, Coombe J, Temple-Smith M, Tomnay J, Vaisey A, Hocking JS. 'It's literally giving them a solution in their hands': the views of young Australians towards patient-delivered partner therapy for treating chlamydia. Sex Transm Infect. 2021 Jun;97(4):256-260. doi: 10.1136/sextrans-2020-054820. Epub 2021 Jan 13. PMID: 33441448.
Copy Download .nbib Format: NLM
Access to Assistive Technology during the COVID-19 Global Pandemic: Voices of Users and Families.

International journal of environmental research and public health

Layton N, Mont D, Puli L, Calvo I, Shae K, Tebbutt E, Hill KD, Callaway L, Hiscock D, Manlapaz A, Groenewegen I, Sidiqi M.
PMID: 34769793
Int J Environ Res Public Health. 2021 Oct 27;18(21). doi: 10.3390/ijerph182111273.

The SARS COVID-19 pandemic emerged in 2019 and has impacted people everywhere. Disparities in impact and outcomes are becoming apparent for individuals and communities which go beyond the trajectory of the disease itself, influenced by the strength and weaknesses...

Cite
Layton N, Mont D, Puli L, et al. Access to Assistive Technology during the COVID-19 Global Pandemic: Voices of Users and Families. Int J Environ Res Public Health. 2021;18(21)doi: 10.3390/ijerph182111273.
Layton, N., Mont, D., Puli, L., Calvo, I., Shae, K., Tebbutt, E., Hill, K. D., Callaway, L., Hiscock, D., Manlapaz, A., Groenewegen, I., & Sidiqi, M. (2021). Access to Assistive Technology during the COVID-19 Global Pandemic: Voices of Users and Families. International journal of environmental research and public health, 18(21), . https://doi.org/10.3390/ijerph182111273
Layton, Natasha, et al. "Access to Assistive Technology during the COVID-19 Global Pandemic: Voices of Users and Families." International journal of environmental research and public health vol. 18,21 (2021). doi: https://doi.org/10.3390/ijerph182111273
Layton N, Mont D, Puli L, Calvo I, Shae K, Tebbutt E, Hill KD, Callaway L, Hiscock D, Manlapaz A, Groenewegen I, Sidiqi M. Access to Assistive Technology during the COVID-19 Global Pandemic: Voices of Users and Families. Int J Environ Res Public Health. 2021 Oct 27;18(21). doi: 10.3390/ijerph182111273. PMID: 34769793; PMCID: PMC8583592.
Copy Download .nbib Format: NLM
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.

The Prostate

Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, Lewis BE, Nakazawa M, Zhu J, Dellinger B, Elrefai S, Nafissi NN, Egan JB, Shore N, McKay RR, Bryce AH, Cheng HH, Antonarakis ES, Sartor O.
PMID: 33792945
Prostate. 2021 May;81(7):433-439. doi: 10.1002/pros.24123. Epub 2021 Apr 01.

BACKGROUND: The goal of this study is to evaluate germline genetic variants in African American men with metastatic prostate cancer as compared to those in Caucasian men with metastatic prostate cancer in an effort to understand the role of...

Cite
Ledet EM, Burgess EF, Sokolova AO, et al. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate. 2021;81(7):433-439doi: 10.1002/pros.24123.
Ledet, E. M., Burgess, E. F., Sokolova, A. O., Jaeger, E. B., Hatton, W., Moses, M., Miller, P., Cotogno, P., Layton, J., Barata, P., Lewis, B. E., Nakazawa, M., Zhu, J., Dellinger, B., Elrefai, S., Nafissi, N. N., Egan, J. B., Shore, N., McKay, R. R., Bryce, A. H., Cheng, H. H., Antonarakis, E. S., & Sartor, O. (2021). Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. The Prostate, 81(7), 433-439. https://doi.org/10.1002/pros.24123
Ledet, Elisa M, et al. "Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer." The Prostate vol. 81,7 (2021): 433-439. doi: https://doi.org/10.1002/pros.24123
Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, Lewis BE, Nakazawa M, Zhu J, Dellinger B, Elrefai S, Nafissi NN, Egan JB, Shore N, McKay RR, Bryce AH, Cheng HH, Antonarakis ES, Sartor O. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate. 2021 May;81(7):433-439. doi: 10.1002/pros.24123. Epub 2021 Apr 01. PMID: 33792945; PMCID: PMC8252583.
Copy Download .nbib Format: NLM
Small bowel diverticulosis: imaging appearances, complications, and pitfalls.

Clinical radiology

Lamb R, Kahlon A, Sukumar S, Layton B.
PMID: 35012738
Clin Radiol. 2022 Jan 07; doi: 10.1016/j.crad.2021.12.003. Epub 2022 Jan 07.

Diverticula of the small bowel can be categorised as true, with Meckel's being the only example, or false. False small bowel diverticula (SBD) are acquired through herniation of the internal layers of the bowel wall through the muscularis propria....

Cite
Lamb R, Kahlon A, Sukumar S, et al. Small bowel diverticulosis: imaging appearances, complications, and pitfalls. Clin Radiol. 2022;doi: 10.1016/j.crad.2021.12.003.
Lamb, R., Kahlon, A., Sukumar, S., & Layton, B. (2022). Small bowel diverticulosis: imaging appearances, complications, and pitfalls. Clinical radiology, . https://doi.org/10.1016/j.crad.2021.12.003
Lamb, R, et al. "Small bowel diverticulosis: imaging appearances, complications, and pitfalls." Clinical radiology vol. (2022). doi: https://doi.org/10.1016/j.crad.2021.12.003
Lamb R, Kahlon A, Sukumar S, Layton B. Small bowel diverticulosis: imaging appearances, complications, and pitfalls. Clin Radiol. 2022 Jan 07; doi: 10.1016/j.crad.2021.12.003. Epub 2022 Jan 07. PMID: 35012738.
Copy Download .nbib Format: NLM
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.

Frontiers in oncology

Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA.
PMID: 33194712
Front Oncol. 2020 Oct 22;10:581189. doi: 10.3389/fonc.2020.581189. eCollection 2020.

No abstract available.

Cite
Barata P, Hatton W, Desai A, et al. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Front Oncol. 2020;10:581189doi: 10.3389/fonc.2020.581189.
Barata, P., Hatton, W., Desai, A., Koshkin, V., Jaeger, E., Manogue, C., Cotogno, P., Light, M., Lewis, B., Layton, J., Sartor, O., Basu, A., Kilari, D., Emamekhoo, H., & Bilen, M. A. (2020). Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Frontiers in oncology, 10581189. https://doi.org/10.3389/fonc.2020.581189
Barata, Pedro, et al. "Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort." Frontiers in oncology vol. 10 (2020): 581189. doi: https://doi.org/10.3389/fonc.2020.581189
Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Front Oncol. 2020 Oct 22;10:581189. doi: 10.3389/fonc.2020.581189. eCollection 2020. PMID: 33194712; PMCID: PMC7642690.
Copy Download .nbib Format: NLM
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.

NPJ vaccines

Marsh GA, McAuley AJ, Au GG, Riddell S, Layton D, Singanallur NB, Layton R, Payne J, Durr PA, Bender H, Barr JA, Bingham J, Boyd V, Brown S, Bruce MP, Burkett K, Eastwood T, Edwards S, Gough T, Halpin K, Harper J, Holmes C, Horman WSJ, van Vuren PJ, Lowther S, Maynard K, McAuley KD, Neave MJ, Poole T, Rootes C, Rowe B, Soldani E, Stevens V, Stewart CR, Suen WW, Tachedjian M, Todd S, Trinidad L, Walter D, Watson N, Drew TW, Gilbert SC, Lambe T, Vasan SS.
PMID: 33972565
NPJ Vaccines. 2021 May 10;6(1):67. doi: 10.1038/s41541-021-00315-6.

Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials,...

Cite
Marsh GA, McAuley AJ, Au GG, et al. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. NPJ Vaccines. 2021;6(1):67doi: 10.1038/s41541-021-00315-6.
Marsh, G. A., McAuley, A. J., Au, G. G., Riddell, S., Layton, D., Singanallur, N. B., Layton, R., Payne, J., Durr, P. A., Bender, H., Barr, J. A., Bingham, J., Boyd, V., Brown, S., Bruce, M. P., Burkett, K., Eastwood, T., Edwards, S., Gough, T., Halpin, K., Harper, J., Holmes, C., Horman, W. S. J., van Vuren, P. J., Lowther, S., Maynard, K., McAuley, K. D., Neave, M. J., Poole, T., Rootes, C., Rowe, B., Soldani, E., Stevens, V., Stewart, C. R., Suen, W. W., Tachedjian, M., Todd, S., Trinidad, L., Walter, D., Watson, N., Drew, T. W., Gilbert, S. C., Lambe, T., & Vasan, S. S. (2021). ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. NPJ vaccines, 6(1), 67. https://doi.org/10.1038/s41541-021-00315-6
Marsh, Glenn A, et al. "ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets." NPJ vaccines vol. 6,1 (2021): 67. doi: https://doi.org/10.1038/s41541-021-00315-6
Marsh GA, McAuley AJ, Au GG, Riddell S, Layton D, Singanallur NB, Layton R, Payne J, Durr PA, Bender H, Barr JA, Bingham J, Boyd V, Brown S, Bruce MP, Burkett K, Eastwood T, Edwards S, Gough T, Halpin K, Harper J, Holmes C, Horman WSJ, van Vuren PJ, Lowther S, Maynard K, McAuley KD, Neave MJ, Poole T, Rootes C, Rowe B, Soldani E, Stevens V, Stewart CR, Suen WW, Tachedjian M, Todd S, Trinidad L, Walter D, Watson N, Drew TW, Gilbert SC, Lambe T, Vasan SS. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. NPJ Vaccines. 2021 May 10;6(1):67. doi: 10.1038/s41541-021-00315-6. PMID: 33972565; PMCID: PMC8110954.
Copy Download .nbib Format: NLM
Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials.

Radiology

Krishnan AP, Song Z, Clayton D, Gaetano L, Jia X, de Crespigny A, Bengtsson T, Carano RAD.
PMID: 34904871
Radiology. 2021 Dec 14;211528. doi: 10.1148/radiol.211528. Epub 2021 Dec 14.

Background Deep learning-based segmentation could facilitate rapid and reproducible T1 lesion load assessments, which is crucial for disease management in multiple sclerosis (MS). T1 unenhancing and contrast-enhancing lesions in MS are those that enhance or do not enhance after...

Cite
Krishnan AP, Song Z, Clayton D, et al. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials. Radiology. 2021;211528doi: 10.1148/radiol.211528.
Krishnan, A. P., Song, Z., Clayton, D., Gaetano, L., Jia, X., de Crespigny, A., Bengtsson, T., & Carano, R. A. D. (2021). Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials. Radiology, 211528. https://doi.org/10.1148/radiol.211528
Krishnan, Anitha Priya, et al. "Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials." Radiology vol. (2021): 211528. doi: https://doi.org/10.1148/radiol.211528
Krishnan AP, Song Z, Clayton D, Gaetano L, Jia X, de Crespigny A, Bengtsson T, Carano RAD. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials. Radiology. 2021 Dec 14;211528. doi: 10.1148/radiol.211528. Epub 2021 Dec 14. PMID: 34904871.
Copy Download .nbib Format: NLM
Showing 313 to 319 of 319 entries